Fidaxomicin versus vancomycin for Clostridium difficile infection

Clicks: 380
ID: 269114
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #77 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The rates of clinical cure after treatment with fidaxomicin were noninferior to those after treatment with vancomycin. Fidaxomicin was associated with a significantly lower rate of recurrence of C. difficile infection associated with non–North American Pulsed Field type 1 strains. (Funded by Optimer …
Reference Key
tj2011thefidaxomicin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Louie TJ;Miller MA;Mullane KM;Weiss K;Lentnek A;Golan Y;Gorbach S;Sears P;Shue YK; ;;
Journal The New England journal of medicine
Year 2011
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/21288078
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male aged middle aged Comparative Study Prospective Studies Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study anti-bacterial agents / adverse effects microbial sensitivity tests feces / microbiology intention to treat analysis anti-bacterial agents / therapeutic use* anti-bacterial agents / pharmacokinetics secondary prevention enterocolitis vancomycin / adverse effects vancomycin / therapeutic use* investigators=[] affs=[]) pmid:21288078 doi:10.1056/nejmoa0910812 thomas j louie mark a miller collabauthor(name='opt-80-003 clinical study group' aminoglycosides / adverse effects aminoglycosides / pharmacokinetics aminoglycosides / therapeutic use* clostridioides difficile* / classification clostridioides difficile* / drug effects clostridioides difficile* / isolation & purification clostridium infections / drug therapy* pseudomembranous / drug therapy fidaxomicin vancomycin / pharmacokinetics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.